Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.

10 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Scientists from the USA and Canada have recently demonstrated that the dynamics of antibody response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) vaccines are different.

31 Aug 2021

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

Aptamer Group Ltd and Bio-Works Technologies AB today announce that they have entered into an agreement to co-develop a new affinity resin.

From Aptamer Group 26 Aug 2021

Reassuring news about the protection that SARS-CoV-2 vaccines offer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have proven effective at preventing COVID-19-related mortality and illness. Since no vaccine is 100% effective, breakthrough infections are likely to occur. New research by a group of scientists at Erasmus Medical Center and Radboud University in the Netherlands looked at vaccine-breakthrough infections in a large group of vaccinated healthcare workers (HCWs).

25 Aug 2021

One billion doses of Oxford-AstraZeneca COVID-19 vaccine released

The University of Oxford's and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca's joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

4 Aug 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Scientists restore memory in aging mice

Scientists at Cambridge and Leeds have successfully reversed age-related memory loss in mice and say their discovery could lead to the development of treatments to prevent memory loss in people as they age.

22 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Gene therapy shows promise in children with devastating genetic disorder

Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.

12 Jul 2021

Novel method of gene therapy promises to transform the treatment of rare genetic disorder

A novel method of gene therapy is helping children born with a rare genetic disorder called AADC deficiency that causes severe physical and developmental disabilities.

12 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

PerkinElmer to buy SIRION Biotech

PerkinElmer Inc. agreed to buy SIRION Biotech GmbH, a provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

From Revvity 24 Jun 2021

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Recently, researchers discuss their development of cell membrane-based nanoparticles that successfully delivered dexamethasone directly to inflamed lung cells.

21 Jun 2021

Immune cell-mimicking nanoparticles deliver drugs directly to inflamed lungs

Nanoengineers at the University of California San Diego have developed immune cell-mimicking nanoparticles that target inflammation in the lungs and deliver drugs directly where they're needed. As a proof of concept, the researchers filled the nanoparticles with the drug dexamethasone and administered them to mice with inflamed lung tissue.

17 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

SARS-CoV-2 oral vaccine booster shows promise in animal tests

In a recent study published on the pre-print bioRxiv* server, a group of Israeli researchers discusses their progress towards developing an oral multi-antigen SARS-CoV-2 vaccine.

15 Jun 2021

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

9 Jun 2021